Skip to content
Investors Dashboard
Contact
TwitterFacebookInstagramLinkedinYouTube
  • English
TwitterFacebookInstagramLinkedinYouTube
  • English
Pharmamar S.A
Pharmamar S.A.
Pharmamar S.APharmamar S.A
  • About PharmaMar
    • Senior Management
    • Management Team Oncology Unit
    • Management Team Virology Unit
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • R&D and Innovation
    • Virology Unit
      • Our Vision
      • Molecular Pharmacodynamics
      • COVID-19, Clinical Development
      • COVID-19, Translational Strategy
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Interim financial information
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Shares Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
    • Contact
    • Merger PharmaMar-Zeltia
    • Política de Comunicación con Accionistas
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
  • Careers
    • Benefits
    • Send us your CV
    • About PharmaMar
      • Senior Management
      • Management Team Oncology Unit
      • Management Team Virology Unit
      • Board of directors
      • Other Business
      • PharmaMar in the World
      • Corporate Responsibility
      • Our History
    • Patients
      • Therapeutic Indications
      • Collaboration with Patient Associations
      • Clinical trial
    • Products
      • YONDELIS®
      • Lurbinectedin
    • Science & Innovation
      • R&D and Innovation
      • Virology Unit
        • Our Vision
        • Molecular Pharmacodynamics
        • COVID-19, Clinical Development
        • COVID-19, Translational Strategy
      • Oncology Pipeline
      • Cofinanced Projects
      • Collaboration with Scientific Associations
      • Publications
      • Mechanisms of Action
      • Medical meeting presentations
    • Shareholders and Investors
      • Financial Information
        • Annual Reports
        • Interim financial information
        • Financial Statements (Zeltia)
        • Average Period of Payment to Suppliers
      • Notifications sent to CNMV
      • Share Information
        • Share Performance
        • Shares Outstanding
        • Dividends
        • Significant Shareholding & Company Owned-Stock
        • Analysts
      • Debt Obligations
      • Presentations
      • General Shareholders Meetings
      • Corporate Governance
        • Corporate Bylaws
        • General Shareholders’ Meeting Regulations
        • Shareholder Agreements
        • Board of Directors
        • Board of Directors Regulation
        • Annual Report on Corporate Governance
        • Annual Director Remuneration Report
        • Board Committees
        • Internal Regulation Governing Conduct
      • Contact
      • Merger PharmaMar-Zeltia
      • Política de Comunicación con Accionistas
    • Newsroom
      • Press Releases
      • Events calendar
      • Multimedia
        • Videos
        • Infographics
      • Medical meeting presentations
    • Careers
      • Benefits
      • Send us your CV

    Category Archives: Press Release

    You are here:
    1. Home
    2. Category "Press Release"

    PharmaMar announces positive results of its APLICOV trial against COVID-19

    Press ReleaseBy admin16 October, 2020

    PharmaMar signs an agreement with Jazz Pharmaceuticals for lurbinectedin in Canada

    Press ReleaseBy admin15 October, 2020

    PharmaMar presents new data on Yondelis® (trabectedin) in combination with immunotherapy at ESMO

    Press ReleaseBy admin21 September, 2020

    PharmaMar has presented new results for ZepzelcaTM (lurbinectedin) in sensitive patients with Small-Cell Lung Cancer, candidates for “re-challenge”

    Press ReleaseBy admin17 September, 2020

    PharmaMar will present data for ZepzelcaTM (lurbinectedin) and Yondelis® (trabectedin) at ESMO 2020

    Press ReleaseBy admin14 September, 2020

    PharmaMar crea una nueva Unidad de Virología

    Press ReleaseBy admin8 September, 2020

    PharmaMar signs a new agreement with Onko to commercialize Yondelis® in Turkey

    Press ReleaseBy admin10 August, 2020

    PharmaMar Group reported net profit of €113.8M at June 30th, 2020

    Press ReleaseBy admin30 July, 2020

    PharmaMar signs a new agreement with ADIUM PHARMA S.A. to commercialize Yondelis® in Latin America

    Press ReleaseBy admin27 July, 2020

    PharmaMar has filed lurbinectedin for Temporary Marketing Authorisation with the Swiss Agency for Therapeutic Products

    Press ReleaseBy admin20 July, 2020
    12345…
    67891011121314151617181920212223242526
    27
     Dream-Theme — truly premium WordPress themes
    Sobre PharmaMar
    Go to Top
    We use our own and third-party cookies in order to collect statistical information and to ensure the best experience on our site. If you want to accept them, click I agree.I agreeI do not acceptPrivacy policy
    You can revoke your consent any time using the Revoke consent button.Revoke consent